NextVivo develops 3D immune organoid models that retain key immune cell types and functional interactions for drug development. These human-derived models allow for the generation and testing of safer, more effective cell and antibody therapies. The technology recapitulates primary immune defense mechanisms to address diseases like cancer, infections, and autoimmune disorders.
Funding
$9.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development relies on pre-clinical models that often fail to accurately predict human immune responses, leading to ineffective therapies and costly clinical trial failures. Traditional 2D cell cultures and animal models lack the complexity of human immune tissues, hindering the identification of effective drug candidates for diseases like cancer, infections, and autoimmune disorders.
Solution
NextVivo offers 3D immune organoid technology that creates human-derived tissue models, enabling the testing of cell and antibody therapies in a controlled environment that mimics the human immune system. These organoids retain key immune cell types and their functional interactions, providing a holistic model of healthy and diseased tissue. By recapitulating the primary defense mechanisms of the immune system, NextVivo's platform allows researchers to generate and test human-derived therapies, improving the selection of promising pre-clinical candidates. This approach aims to develop safer, more effective therapies by testing them in immune-competent, human-derived models.
Target Audience
The primary audience includes pharmaceutical companies, biotech firms, and research institutions involved in drug discovery and development, particularly those focused on immunotherapies for cancer, infectious diseases, and autoimmune disorders.
Features
- 3D organoid models derived from human tissue
- Retention of key immune cell types and functional interactions
- Mimicry of primary defense mechanisms of the human immune system
- Controlled environment for testing cell and antibody therapies
- Models for healthy and diseased tissue